Rodrigo Lago, MD
Cardiovascular Disease · Apopka, FLNPI 1821269697
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 68.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $7,230 and has fallen 94.3% since, to $410 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 80 payments — averaging $337.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$18K
- Boehringer Ingelheim$5K
- Abbott$2K
- Edwards Lifesciences$412
- Medtronic$296
- Impulse Dynamics (USA) Inc.$162
- plus $460 from 11 others
Across 31 payments — averaging $1603.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$50K
What the payments were for
- Consulting fees$14,30053%
- Speaking & faculty fees$4,72618%
- Travel & lodging$3,48813%
- Food & beverage$4,47117%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 24 | $18,468 |
| Boehringer Ingelheim | 2 | $4,753 |
| Abbott | 25 | $2,434 |
| Edwards Lifesciences | 7 | $412 |
| Medtronic | 4 | $296 |
| Impulse Dynamics (USA) Inc. | 1 | $162 |
| Heartflow, Inc. | 4 | $109 |
| Atricure, Inc. | 3 | $92 |
| Kestra Medical Technology Services, Inc. | 1 | $84 |
| Novartis | 2 | $32 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $31 |
| Philips North America LLC | 1 | $22 |
| Teleflex LLC | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Abiomed | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Pfizer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$9,287
- GENERAL VASCULAR ACCESS$4,917
- JARDIANCE$4,726
- GENERAL - STRUCTURAL HEART$4,000
- OPTIMIZER$324
- MitraClip$284
- AMPLATZER Occluders$187
- NAVITOR$156
- Trifecta GT Tissue Heart Valve$150
- APOLLOTM$144
- COREVALVE EVOLUT R$116
- SAPIEN 3 Ultra RESILIA$107
- GENERAL - STENTS$102
How this compares
$26,985 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 61 | $60,574 |
| EntrestoSacubitril/Valsartan | 18 | $23,186 |
| XareltoRivaroxaban | 12 | $16,449 |
| JardianceEmpagliflozin | 11 | $14,795 |
| BrilintaTicagrelor | 19 | $8,691 |
| Valsartan | 16 | $854 |
| Rosuvastatin Calcium | 72 | $852 |
| Carvedilol | 73 | $668 |
| Losartan Potassium | 52 | $593 |
| Ezetimibe | 56 | $581 |
| ClopidogrelClopidogrel Bisulfate | 36 | $570 |
| Ranolazine ErRanolazine | 16 | $552 |
| Atorvastatin Calcium | 48 | $413 |
| Bumetanide | 12 | $332 |
| Spironolactone | 36 | $230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $17 | $60,57461 claims |
| NovartisEntresto | $32 | $23,18618 claims |
| Boehringer IngelheimJardiance | $4,753 | $14,79511 claims |
| AstraZenecaBrilinta | $17 | $8,69119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Apopka
- Cesar Bonilla IsazaApopka$107K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.